-
-
-
-
-
-
-
FDA panel votes against Capricor's Deramiocel for DMD heart disease
-
-
-
-
-
-
-
Evommune starts Phase 2b trial of EVO756 for migraine prevention
-
-
-
-
-
-
-
Athabasca Oil posts Q2 results as Leismer expansion advances
-
-
-
-
-
-
-
FDA grants RMAT designation to Ocugen's OCU410 for dry AMD
-
-
-
-
-
-
-
Adia Med completes Phase 1, launches Phase 2 of ASD study
-
-
-
-
-
-
-
study links NR supplement to reduced muscle epigenetic aging marker
-
-
-
-
-
-
-
Enveric Biosciences responds to FDA final guidance on psychedelic drug development
-
76,539 total articles have been posted to this category.
Sign-up to StreetInsider.com Premium
to see all today's market moving FDA reports.

